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abstract
PURPOSE The coronavirus-induced pandemic has put great pressure on health systems worldwide. Non-
emergency health services, such as cancer screening, have been scaled down or withheld as a result of travel
restrictions and resources being redirected to manage the pandemic. The present article discusses the
challenges to cancer screening implementation in the pandemic environment, suggesting ways to optimize
services for breast, cervical, and colorectal cancer screening.
METHODS The manuscript was drafted by a team of public health specialists with expertise in implementation
and monitoring of cancer screening. A scoping review of literature revealed the lack of comprehensive guidance
on continuation of cancer screening in the midst of waxing and waning of infection. The recommendations in the
present article were based on the advisories issued by different health agencies and professional bodies and the
authors’ understanding of the best practices to maintain quality-assured cancer screening.
RESULTS A well-coordinated approach is required to ensure that essential health services such as cancer
management are maintained and elective services are not threatened, especially because of resource con-
straints. In the context of cancer screening, a few changes in invitation strategies, screening and management
protocols and program governance need to be considered to fit into the new normal situation. Restoring public
trust in providing efficient and safe services should be one of the key mandates for screening program re-
organization. This may be a good opportunity to introduce innovations (eg, telehealth) and consider de-
implementing non–evidence-based practices. It is necessary to consider increased spending on primary health
care and incorporating screening services in basic health package.
CONCLUSION The article provides guidance on reorganization of screening policies, governance, imple-
mentation, and program monitoring.
JCO Global Oncol 7:416-424. © 2021 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License
INTRODUCTION
The SARS-CoV-2 infection responsible for the first
pandemic of the twenty-first century already claimed
more than 2 million lives as of January 2021.1 Health
system in every country is strained to the extreme as a
result of the impact of the COVID-19 pandemic. Ser-
vices deemed nonemergency such as cancer screening
were scaled down or stopped as part of efforts to reduce
risks of SARS-CoV-2 infection and also to reduce load
on the health services. Measures to avoid nonurgent
interactions with health facilities were endorsed by the
WHO and the respective Ministry of Health during the
acute phase of the transmission in the community.2
Different professional medical societies and voluntary
organizations also advised to put cancer screening on
hold.3,4 Most importantly, the screen-eligible individuals
were hesitant to visit the health facilities because of the
scare of getting the infection. As a consequence, a
significant surge in the number of deaths from cancer
and other diseases unrelated to COVID-19 is predicted
in the near future, especially in the socioeconomically
disadvantaged and other vulnerable populations.5
As the countries ease restrictions and reopen various
essential health care facilities, putting cancer
screening and management back on track will con-
tinue to face challenges. A survey conducted by the
WHO in May 2020 in 155 countries not only reported
major disruption of noncommunicable disease (NCD)
control services (including cancer screening) in almost
all countries but also highlighted the difficulties of
reinitiating such activities.2 Full or partial assignment
of the dedicated health staff for NCD control to support
COVID-19 in 94% of the responding countries is one
such example. Several countries have already reported
more than 90% drop in screening, diagnostic, and
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emergency because of COVID-19.6-8 Scotland reported a
70% reduction in urgent referrals of patients with sus-
pected cancer by primary care physicians during the surge
of COVID-19 cases, and such drastic reduction in referrals
will significantly delay cancer detection.9,10
The public health policies and social measures adopted by
the countries to respond to the pandemic are different, and
there is no one size fits all solution to reorient health service
components and maintain the nonemergency preventive
services. Restarting cancer screening activities as the crisis
situation continues or somewhat settles down will require a
well-coordinated effort to reach out to the community more
proactively, alleviate the concerns of the apparently healthy
individuals to return to routine health care and reorganize
clinical services to minimize backlogs in services.
The objectives of this article are to enumerate the chal-
lenges at health system level for reinitiating cancer
screening services in the post-COVID scenario and to
CONTEXT
Key Objective
What are the challenges at health system level for reinitiating cancer screening in the postpandemic scenario, and how to
optimize screening services by making them resilient to similar contextual threats?
Knowledge Generated
Restarting cancer screening activities in the post-COVID era will require a well-coordinated effort to reach out to the community
more proactively, alleviate the concerns of the apparently healthy individuals to return to routine health care and reorganize
clinical services to minimize backlogs in services. This should be considered as an opportunity to improve organization,
quality, and reach of the cancer screening programs through pragmatic application of technology and innovations and de-
implementation of existing non–evidence-based practices.
Relevance
The best practices in governance, organization, and implementation highlighted in the article will help the cancer screening
programs to encounter disruptive consequences of the pandemic better and thus prevent the predicted surge in the
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FIG 1. Illustration of the impact on
cancer screening activities of the
COVID-19 epidemic phases.
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suggest various approaches to optimize services for breast,
cervical, and colorectal cancer (CRC) screening and im-
prove their resilience to contextual threats.
COVID PANDEMIC—DIFFERENT SCENARIOS AND THEIR
LIKELY IMPACT ON PUBLIC HEALTH INTERACTIONS
Characteristically, the unfolding of the COVID-19 epidemic
occurs through a sequence of phases with different levels of
infection transmission and burden of disease in the pop-
ulation (Fig 1). In the first phase, when effective mitigation
measures are not yet in place, the number of cases grows
exponentially, and health care systems may get over-
whelmed with management of the symptomatic cases.
Consequently, routine activities are severely disrupted and
most nonurgent medical activities are temporarily sus-
pended. In the second phase, if public health control
measures are effective, infection transmission slows down
and the number of new infections decreases. In the ab-
sence of an effective vaccine, several waves of exponential
growth may occur, until a sufficient fraction of the pop-
ulation has developed protective immunity against the in-
fection, at this point the epidemic declines and enters in the
extinction phase (not yet observed with SARS-CoV-2).
The stringency of public health control measures and re-
strictions is modulated according to the intensity of each
phase of the epidemic; the ability of health care facilities to
deal with routine activities is affected correspondingly. In
very acute phases of the epidemic, available human and
technologic resources are mostly reallocated from routine
health care activities to COVID-19 response. Subsequently,
during less acute phases of the epidemic, the health care
system not only resumes routine actions with limited re-
sources and workforce but also faces a substantial backlog
of activities. In the context of screening programs, the ef-
ficiency of the program has to be significantly augmented
within a short period to cope with these pending residual
activities. Of note, program’s efficiency will be further
negatively affected by logistical measures put in place to
protect screening participants from the risk of SARS-CoV-2
transmission.
POLICIES, GOVERNANCE, AND COORDINATION OF
CANCER SCREENING
Ministries of Health should be alerted to the fact that cancer
is an ongoing pandemic, which is fast approaching the
milestone of claiming nearly 10 million lives every year.12
Undeniably, decision making and balancing the demand of
so many competing health priorities even as the SARS-CoV-
2 outbreak moves to a less acute phase will be extremely
challenging for policy makers. There is a possibility that
economic slowdown and reallocation of public health re-
sources to pandemic response will be put forward as a
justification to reduce funding for NCD control. A well-
coordinated approach is required to ensure that essential
health services are maintained and routine and elective
services are not threatened, especially because of resource
constraints, fostering a sense of public trust. Hospitals or
clinics aiming to initiate cancer screening and other es-
sential health services should create COVID-protected
areas segregated from the movement of known or sus-
pected COVID individuals. These protected areas should be
routinely cleaned and decontaminated, and both staff and
screening attendees should follow the norms of personal
protection.
Until a significant proportion of the population is vaccinated
with any of the available vaccines against SARS-CoV-2, the
course of the outbreak is likely to wax and wane, and the
strategic responses need to be dynamic and in sync with
the situation. There are governance and coordination
TABLE 1. Governance and Coordination Mechanisms to Optimize Cancer
Screening and Downstream Activities
Every country now has a national COVID-19 response team. A designated cancer
(or NCD) control focal person should be part of this team. The
recommendations of the team should include strategic guidance on the
intensity and protocol of cancer screening.
A channel for regular communication and coordination between COVID-19
response team, screening program managers, and relevant stakeholders
should be established to permit continued assessment of benefit versus risk of
continuing with screening activities during ongoing transmission.
Rapid assessments will help understand the challenges and barriers in service
delivery created by the pandemic and how they can be solved through policy
and protocol changes; phased prioritization of services; pragmatic allocation of
human, financial, andmaterial resources; and adaptation of new technologies.
A guideline for maintaining screening, diagnostic, and treatment service delivery
adapted to the new situation should be published as has already been done by
some countries.11
Capacity of the health facilities to provide screening, diagnostic, and treatment
services should be augmented to handle increased demand without
compromising on the safety of the participants.
Relocating services away from health facilities with patients with COVID-19
(creation of COVID-free hubs) should be prioritized for patients with cancer
and can be gradually expanded to provide screening-related services,
depending on resource availability. If establishing such hubs is not feasible,
COVID and non-COVID (which includes cancer screening and treatment)
services should be clearly demarcated within the facility.
A system of stock inventory and supply chain management should be initiated to
ensure availability of PPE kits and other essential consumables needed for
screening and management for at least 30 days.
Both quality and capacity of the information system that captures screening-
related activities should be augmented to ensure a rapid and adaptive
response to change.
The economic downturn will make the population more cost-sensitive.
Ensuring financial protection (either making the services free or bringing them
under insurance coverage) will improve participation in screening and
management.
Abbreviations: NCD, noncommunicable disease; PPE, personal protective
equipment.
aAustralian Government Department of Health: Guidance for managing National
Cervical Screening Program (NCSP) participants during the COVID-19 pandemic.
http://www.cancerscreening.gov.au/internet/screening/publishing.nsf/Content/
guidance-for-managing-ncsp-participants-during-the-covid-19-pandemic.
Accessed October 21, 2020.
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mechanisms that might help to optimize cancer screening
and downstream activities, and these are listed in Table 1.
One of the key requirements would be to increase spending
on primary health care by at least 1% of the GDP, which
according to theWHO is within the capacity of even the low-
income countries.13
There are still uncertainties around the appropriate
policy to return health care workers to service or per-
mitting nonemergency attendance of patients to the
hospitals after a positive SARS-CoV-2 test. Although most
health facilities would recommend a negative test ob-
tained after the resolution of symptoms, some institutions
might exclude health care workers and patients until a
fixed period of time since symptom recovery. Four weeks
may be a safer interval between symptom onset and
nonemergency contact with health facilities when real-
time reverse transcription polymerase chain reaction
cannot be repeated.14
COMMUNITY MOBILIZATION AND EFFECTIVE
COMMUNICATION STRATEGIES
The infodemic associated with COVID-19 has generated a
lot of myths and misconceptions that are likely to have a
lasting impact on cancer screening services. It is important
to understand the concerns of the screen-eligible individ-
uals through sample surveys or qualitative research, which
will help the program restructure strategies for invitation
and community mobilization. Clear messaging from all
stakeholders on the need to continue cancer screening and
publicizing the robustness of the safety measures at the
health facilities associated with screening would create
public trust and improve their care-seeking behavior. Major
policy changes (eg, reopening of cancer screening activi-
ties) should be widely publicized through mass media.
Screening programs with systematic invitation strategies
should inform the eligible populations through letters,
emails, telephone calls, or digital platforms about the
measures taken by the program to minimize the risk of
SARS-CoV-2 transmission. The opportunistic programs
should ensure that the health staff entrusted to mobilize
individuals for screening are appropriately trained to pro-
vide such information in an unambiguous manner. In some
countries (eg, Thailand or India), community health
workers make home visits to counsel and invite individuals
to cancer screening. Creative use of mobile phones and
innovative apps may help the health workers to contact
eligible individuals more efficiently while minimizing
person-to-person contact. Cancer awareness campaigns
should aim to improve public health literacy on the con-
sequences of delaying screening, diagnosis, and treatment
and involve various stakeholders, including the NGOs and
faith-based organizations. Informing populations of the
early symptoms of common cancers and the conse-
quences of ignoring them because of the outbreaks should
be a key component of all campaigns.
MANAGING SCREENING INVITATIONS OR OFFERING
SCREENING IN OPPORTUNISTIC SETTINGS
COVID-19 creates major disruptions in the systematic in-
vitation procedure with screening appointments being
delayed, deferred, or neglected during the acute phase of
the pandemic. Strategies to deal with the backlog include
increasing the number of screenings performed in a day (by
extending the hours of service or by expanding the ca-
pacity), switching to more throughput testing technologies
(eg, use of quantitative rather than qualitative fecal
immunochemical tests (FITs) for CRC screening and
introducing human papillomavirus [HPV] test for cervical
cancer screening), and task-shifting or -sharing. Health
systems should prioritize inviting those who are at highest
risk (eg, the defaulters to screening, the post-treatment
follow-ups, the women living with HIV for cervical cancer
screening, etc). Individuals with known comorbidities
should be given appointment in a way to minimize wait time
at the health facilities, and some of them with least risk (eg,
women with history of regular and normal cervical cancer
screening nearing the upper age limit) may be spared of
any further screening. Information system should be
adapted and calibrated to be able to manage the new
program strategies in appointment and invitation man-
agement. Helplines or dedicated websites may be set up to
address patient queries.
Opportunistic screening is likely to decline significantly as
the in-person visits by the asymptomatic patients to health
facilities drop significantly during and after the acute
situation.15 Primary care providers need to be more pro-
active in counseling andmotivating the eligible populations.
Remote consultation through telemedicine is becoming
popular in many countries with improved technology and
adoption of regulatory and legal framework.16 These tele-
health opportunities or virtual clinics could be used to invite
eligible men and women to screening. As a result of ra-
tioning of personal protective equipments (PPEs) in the
face of supply shortage, screening appointments may be
given on selected days of the week to examine a large
number of participants on a single day.
ADMINISTERING SCREENING TESTS AND MANAGING
THE SCREEN-POSITIVES
Restoration of screening or diagnostic services should
continue to mitigate the risk of SARS-CoV-2 transmission
and at the same time have contingency plans anticipating
the likelihood of restrictive measures being reintroduced.
Reorganization of screening services as the COVID-19 case
load reduces should focus on capacity enhancement as
well as adopting novel approaches to minimize person-to-
person contact and maintain social distancing. Written
standard operating procedures for infection control should
be circulated among the providers and displayed promi-
nently inside the clinics. Every clinic should have a des-
ignated staff in charge of monitoring compliance to the
Cancer Screening During the COVID-19 Pandemic
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standard operating procedures. Irrespective of the nature of
screening or diagnostic evaluation, the basic principles and
safety protocols as listed in Table 2 should be adhered to in
all settings to minimize SARS-CoV-2 transmission risk. To
reduce the clinic load as a result of backlogs, some tasks
may be delegated to different cadres of health professionals
(task-sharing) or to providers who perform less specialized
work (task-shifting). Retired nurses or clinicians and fresh
medical or nursing school graduates can also be employed.
Such workforce reorganization should be supported by
appropriate revision of the regulations and an effective
training plan. COVID-free cancer-screening hubs may be
created and scaled up in a phased manner depending on
the demand and available resources.
In the following sections, we have discussed the best
practice measures that can be adopted to improve efficiency
of screening for cervical, breast, and colorectal cancers.
REORGANIZING CERVICAL CANCER SCREENING SERVICES
The WHO’s call to eliminate cervical cancer has motivated
efforts across the globe to scale up screening services and
implement HPV-based programs. The HPV-negative
women won’t need any clinic attendance for screening
for at least 5 years. HPV-based screening offers a possibility
of at-home sample collection by the women themselves,
which avoids the use of public transport to clinics and
unnecessary exposure within clinics, thereby reducing risk
to both health care providers and patients. HPV testing
obtained without a gynecologic examination, by women
themselves either at home or clinic, provides a reliable
result.17 The kits for self-collection may be sent by post or
distributed by the community health workers.
Majority of the low- and middle-income countries cannot
afford HPV tests and have to rely on visual inspection with
acetic acid (VIA) test, which requires an examination by a
health provider. In such settings, a screen-and-treat ap-
proach of immediate treatment of the VIA-positive women
will reduce the number of clinic visits by the women and
minimize client-provider interactions. We suggest that the
current situation actually offers an incentive for the VIA
programs to switch to HPV-based screening every 5 or 10
years. Many of the test platforms procured to detect SARS-
CoV-2 virus can be used to detect HPV as well.
Depending on the prevailing travel restrictions and load on
the services, a policy to triage patients for diagnostic
evaluation may be considered. Appropriate triaging of the
HPV-positive women can significantly reduce the number
of women requiring colposcopy. Triaging HPV-positive
women with HPV 16/18 genotyping and cytology (only
for those HPV-positive women negative on HPV 16/18)
reduced colposcopy referrals by nearly two-third in the
screening program in Turkey.18 Those with suspected high-
grade lesions or cancer on cytology should be given priority
appointment for colposcopy over those having low-grade
abnormalities.19 Outreach VIA, colposcopy, and treatment
services, which do not rely on electricity and combine all
these interventions in a single visit, could provide a viable
alternative to clinic visits in resource-constrained settings.20
TABLE 2. Common Safety Protocol to Mitigate Risk of Transmission of SARS-CoV-2 Infection During Screening and Diagnostic Services
Infection mitigation practices prior to client-
provider interaction
Screening and diagnostic test appointment should be given only after checking that the individual does not
have any active symptoms of COVID-19 and no known exposure.
Testing for COVID-19 before issuing appointments may be preferred, but depends on availability of test
facilities.
Appointments should be given through online system or call centers and managed in such a way to avoid
overcrowding of the clinics.
Infection mitigation practices at the clinics Wearing a mask should be mandatory inside the clinic.
Number of accompanying persons should be reduced to aminimum, and the same protective steps should
be applicable to them as well.
Physical facilities at the clinics should be reorganized to ensure adequate physical distancing.
High-risk individuals with comorbidities should be examined first.
All clinic staff should be well-trained on infection control measures. They should use PPE at all interactions
with clinic attendees.
Any staff showing symptoms of COVID-19 should not attend the clinic and immediately inform the clinic
managers; staff should be frequently tested for infection.
Disposable instruments should be used as much as possible.
Infection mitigation practices after
examination
The surfaces of the beds, mammography machines, etc, should be decontaminated after every
examination. Routine infection control measures should be adhered to.
The screening test results should be communicated through text messages, telephone calls, emails, or
online platforms whenever feasible.
The clinics should be decontaminated at the end of the day.
Abbreviation: PPE, personal protective equipment.
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Women living with HIV have substantially increased risk of
cervical cancer. In the current health care landscape, it is
important that screening services continue especially for
this group of women. The WHO has recommended inte-
grating cervical cancer screening services into antiretroviral
therapy programs and screening should be planned at one
of the scheduled visits to the antiretroviral therapy clinic.21
To minimize number of visits, colposcopically suspected
high-grade lesions should be treated immediately without
waiting for histopathologic verification. Observational
studies have documented the presence of HPV DNA (the
type identical to that present in the cervical lesion) in the
smoke generated during large loop excision of transfor-
mation zone (LLETZ) procedure and transmission of HPV
DNA to the operator’s nasal cavity.22,23 No formal study has
yet documented the risk of an operator of getting infected
with SARS-CoV-2 because of the aerosols generated during
LLETZ procedure. A study on 35 patients infected with
SARS-CoV-2 (eight patients were symptomatic) in China
demonstrated that none of them had the virus detected in
vaginal fluid or cervical specimen.24 The British Society of
Colposcopy and Cervical Pathology advises to limit the use
of diathermy to coagulate the bleeding points after LLETZ
(to minimize dispersal of vaporized particles) and liberally
use Monsel’s solution for hemostasis.25 Thermal ablation
and cryotherapy treat the cervical precancerous lesions by
tissue desiccation and freezing, respectively, and do not
generate any smoke. Nevertheless, the use of PPE is
recommended for the provider and assistants while per-
forming colposcopy and treatment of an asymptomatic
patient without known COVID status and it should comprise
sterile fluid-repellent surgical gloves, eye protection, FFP2
mask, surgical cap, and gown.26
REORGANIZING CRC SCREENING SERVICES
Coordinated efforts are necessary to overcome the COVID-
19 challenges and facilitate the resumption of CRC
screening programs in a gradual and prioritized manner.
Selecting candidates according to individual CRC risk with
priority given to high-risk individuals may be considered in a
program on the basis of invitation. This process can be
coordinated with the screening registry staff or general
practitioner who can stratify individuals by risk through
phone calls or administration of online questionnaire. In
addition, scientific societies should revisit some of their
guidelines for patients with inflammatory bowel disease or
postpolypectomy endoscopic surveillance to optimize the
colonoscopy resources.27
Screening and diagnostic services should be reintroduced
in COVID-free centers to mitigate risk of infection and
encourage population to participate. D’Ovidio et al28 con-
ducted a study in Italy to verify the effectiveness and safety
in performing selective diagnostic colonoscopies as part of
the CRC screening program in a hospital declared as
COVID-free hospital. They found that in spite of fewer cases
done during lockdown in comparison with data from the
same period in 2019, both invasive cancer detection rate
(8% v 1%; P = .002) and high-risk adenoma detection rate
(47% v 25%; P = .001) were higher because of the pri-
oritization of more high-risk cases.
During the pandemic, flexibility in CRC screening methods
should be considered. Switching to FIT in programs that
use endoscopy-based screening is an example. Moreover,
applying an FIT test would allow using the mail system to
send and return test kits. Alternatively, the samples can be
deposited in drop boxes kept at health facilities. By
sending the FIT test kits to the eligible individuals by post,
the National Bowel Cancer Screening Program in Aus-
tralia could maintain reasonably high participation rate
to CRC screening even during the worst period of the
COVID-19 outbreak.8 Quantitative FIT should replace
qualitative FIT as it is throughput and reduces the colo-
noscopy referrals.29,30
REORGANIZING BREAST CANCER SCREENING SERVICES
Differently from cervical and colon cancer screening, breast
cancer screening has no alternative for a self-collected
screening test. As the screening activities resume while
the COVID-19 pandemic is still ongoing, breast imaging and
further assessment must be performed using safe prac-
tices. On that note, we must balance the need to avoid
delays of a breast cancer diagnosis while avoiding infection,
which requires careful attention to PPE, physical distanc-
ing, and vigilance to maintain these practices; resuming
activities should also involve prioritization and imple-
mentation of innovative interventions.31
Recommendations from different medical associations and
experts are proposing that the diagnostic procedures in
symptomatic patients should be prioritized over screening
procedures. All efforts should be made to avoid delayed
diagnosis in situations as clinical suspicion of inflammatory
or locally advanced breast cancer, imaging findings of BI-
RADS 5 (high priority) or BI-RADS 4 (medium priority),
symptomatic women with a new palpable lump or breast
thickening that is clinically concerning, and suspicion of
breast cancer in a pregnant woman.31-35
Annual mammographic screening should be discouraged.
One interesting strategy to reduce the number of clinic visits
for the women may be a one-stop breast care. Health fa-
cilities would offer same-day diagnosis and integrated
multidisciplinary care services, which include counseling,
mammography, or clinical breast examination followed by
appropriate diagnostic evaluation, which includes imprint
cytology of breast core biopsy specimens. This model has
been tested in both low- and high-resource settings,
showing encouraging feasibility and outcomes.36,37
ORGANIZING TREATMENT OF PATIENTS WITH CANCER
The COVID pandemic has significantly disrupted treatment
of patients with cancer with patients and the treating
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oncologists being hesitant to initiate or continue with
treatment given the threat of the infection.38 Cancer as a
comorbidity certainly increases the risk of getting severe
complications and dying from COVID.39 However, at least
two studies have shown that cancer treatment does not
increase the threat to life of a patient, even if they get in-
fected during the course of treatment.40,41 Strategies that
should be considered to ensure timely and adequate
treatment of the patients with cancer during various phases
of the pandemic are listed in Table 3.
CONTINUATION OF RESEARCH IN CANCER
EARLY DETECTION
The COVID-19 pandemic has had a huge impact on clinical
research other than those related to the infection and its
prophylaxis or treatment.42 Many clinical trials were put on
hold as there were a lot of uncertainties around the balance
of risks and benefits and how best to communicate the
same to the prospective participants.43 Research evaluat-
ing the efficacy and/or implementation of new technologies
and approaches in cancer early detection will face major
challenges in the near future. IARC planned a multicentric
trial to evaluate automated visual examination (artificial
intelligence–based recognition of cervical lesions) as a
cervical cancer screening tool in India and Thailand.44 The
study initiation has been delayed by at least 10 months
because of less frequent meetings of the ethics commit-
tees, suspension of courier servicesmaking procurement of
consumables and equipment difficult, cessation or slowing
down of cancer screening activities, the investigators being
preoccupied with COVID-related duties, uncertainties
around compliance of the trial participants, and safety
concerns of the participants as well as staff because of the
increased number of interactions. The biotechnology in-
dustries are quite cautious in investing in new innovations
in the midst of the economic downturn. Some of the de-
velopers of new point-of-care HPV detection tests are
investing their energy and resources in new technologies
for the detection of SARS-CoV-2 and postponed the de-
velopment of the HPV tests. The availability of fund for
research will shrink significantly with major research-
funding agencies already announcing major cuts in can-
cer research funding.10
It is crucial to obtain clear directives and guidance from the
national regulatory agencies for continuation of clinical
research. To date, the US Food and Drug Administration
and European Medicines Agency have published such
guidelines.45,46 It will be necessary to modify some of the
regulatory requirements. Remote consenting through
online consultation followed by obtaining a digital signature
(e-consent) and follow-up by telephone or video calls
in situations not requiring sample collection or assessment
by a health provider may become acceptable norms. Ad-
vantage should be taken of the enhanced digital literacy and
acceptance of app-based COVID-19 symptom–reporting
and alert tools to promote self-reporting of outcomes by
trial participants using online platforms. The relationship
between exposure to the trial-related interactions and
subsequent infection with SARS-CoV-2 should be closely
monitored, and appropriate actions should be taken if there
are any concerns. Implementation research to identify the
most pragmatic, acceptable, and cost-effective strategies to
continue with cancer screening and treatment services
during various phases of the epidemic should be prioritized.
In conclusion, reintegration of individuals to the screening
pathway depending on where they left at the time of
suspension requires a coordinated approach and in-
volvement of many stakeholders. It is an opportunity to
learn from other countries as this has become a global
problem and countries are at different stages of adapting
TABLE 3. Strategies to be Considered to Ensure Timely and Adequate Treatment of
the Patients With Cancer During Various Phases of the Pandemic
Standard treatment of patients with cancer should not be deferred or
discontinued until and unless they have evidence of SARS-CoV-2 infection.
Activemonitoring of the waiting list should be done to triage those cases requiring
immediate attention.
Oncology surgeries, especially those that may be curative, should be given
priority in the waiting list. Surgery for early CRC should not be delayed more
than 6 weeks to reduce risk of bowel occlusion, perforation, bleeding, and
cancer progression.a At the same time, symptomatic treatment such as
analgesics should be made available to all patients who require it.
Oncology centers should admit patients after checking that they have no
symptoms suggestive of COVID-19 or they have not been in contact with a
patient with COVID-19. Where possible, it is safer to test all patients routinely
for SARS-CoV-2 with RT-PCR within 72 hours of admission.
During the course of oncologic treatment, patients should be advised isolation as
much as possible at home, because of immunosuppression and susceptibility
to infection.
Arrangements should be made to ensure that the patients with cancer can reach
hospitals on scheduled dates even if there is a movement restriction because
of lockdown or local containment.
Patients with cancer should be well-protected from risk of infection at the
hospitals through adoption of strategies mentioned earlier. Creating COVID-
free hubs away from the acute diseases hospitals can be very reassuring for the
patients.
A pool of staff trained in protective measures should be created to cater to the
patients with cancer. Oncology centers may consider hiring retired staff to
manage the increased demand.
Regular supply of chemotherapy and other essential drugs to maintain treatment
cycles should be ensured.
Radiation therapy facilities need to increase the service hours to accommodate
more patients to manage the backlogs resulting from the lockdowns.
Strategies such as hypofractionated radiation therapy can minimize the
treatment duration and should be considered when appropriate.
A close communication between the oncologists and infectious disease
specialists is needed to appropriatelymanage a patient with cancer detected to
have COVID-19.
Abbreviations: CRC, colorectal cancer; RT-PCR, real-time reverse transcription
polymerase chain reaction.
aVecchione L, Stintzing S, Pentheroudakis G, et al: ESMO management and
treatment adapted recommendations in the COVID-19 era: colorectal cancer.
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cancer screening successfully to the changing health
ecosystem. It is also an opportunity to improve the resil-
ience of screenings to threats, which are likely to arise in a
volatile and uncertain context. In these unprecedented
times, reassessing a cancer screening program could be an
opportunity of building back better services. Performing a
situation analysis and planning accordingly, prioritizing and
keeping focus on evidence-based practices, considering
implementation of evidence-based innovations (eg, telehealth
and new algorithms), and considering de-implementation of
non–evidence-based practices (eg, screening for prostate
or liver cancer, screening off-target age population, etc)
could be a good start point. The key is to remain flexible and
vigilant and periodically assess severity of the outbreak in
the population and adapting guidelines to the changing
situation.
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